Statin Therapy and Stroke Risk in Patients with Hypercholesterolaemia: A population-based Longitudinal Study Using Electronic Health Records in South London

Marc Delord[1,*] and Abdel Douiri[1]

[1]School of Life Course & Population Sciences, Department of Population Health Sciences, King's College London, London, United Kingdom
[*]Correspondence: marc.delord@kcl.ac.uk, Tel: +44 20 7848 8710

Abstract

Background: We aim to evaluate the impact of statin prescription on stroke risk in patients with hypercholesterolaemia and to assess disparities in statin prescribing.

Methods: We analysed electronic health records from patients with hypercholesterolaemia, registered in 41 general practices in south London between 2005 and 2021. The cause-specific hazard ratio of statin prescription on stroke, adjusted for patients' sociodemographic characteristics and stroke risk factors (smoking ever, hypertension, and diabetes), was estimated using a time-varying exposure Cox proportional hazards model stratified by history of heart diseases. The association between statin prescription and patients' sociodemographic characteristics was evaluated using a logistic regression.

Results: Of the 849,968 registered patients, 166,124 (19.5%) had records of hypercholesterolaemia. Among them, 33.5% were prescribed statins, 2.6% had a record of stroke, and 50.6% were female, 31.7%, 16.2% and 8.9% had records of hypertension, diabetes and history of heart diseases respectively. In a Cox model stratified by history of heart diseases, statin prescription was associated with a reduced hazard of stroke (cause-specific hazard ratio: 0.74; 95% confidence interval (CI): 0.68–0.80, p<0.001), with follow-up administratively censored at 79 years (n=161,527; 97.2%). Statins were less likely prescribed to female patients and patients of Black ethnicity (odds-ratio: 0.70, 95% CI: 0.68-0.72, p<0.001 and odds-ratio: 0.82, 95% CI: 0.79-0.85, p<0.001, respectively).

Conclusion: Statin therapy prescription is associated with reduced stroke risk in patients with hypercholesterolaemia, yet it was under-prescribed to women and patients of Black ethnicity, highlighting avoidable disparities in preventive care.

Keywords:

Stroke; Hypercholesterolemia; Statin therapy; Electronic Health Records; Gender Disparity; Ethnic Disparity

Introduction

The relationship between hypercholesterolaemia and stroke has been described as complex [1]. This complexity is due to interacting factors such as cholesterol composition [2], stroke subtypes [2–4], patients' age [5], and the confounding effect of lipid-lowering therapies, particularly statins. For instance, the risk of stroke in patients with familial hypercholesterolaemia (FH), which is associated with high low-density lipoprotein cholesterol (LDL-C) [6], is significantly reduced by the use of statins [7], and recent population-based studies did not report an excess risk of stroke in patients with FH [8, 9]. Despite initial concerns regarding the paradoxical association between cholesterol levels and haemorrhagic stroke [3, 10], statins are considered safe and effective to reduce total stroke risk [5, 11–14].

Importantly, statins reduce the risk of major vascular events, including stroke, irrespective of patients' age, sex, or cardiovascular risk [12, 13], lower risks being associated with more intensive regimens [13]. Statins are also considered remarkably safe drugs, with possible risks of haemorrhagic stroke being outweighed by the protective effect against ischaemic stroke and coronary artery disease [15]. Concerns about statin-related muscle pain were explored in randomised trials suggested no significant difference in muscle symptoms between statin and placebo use [16, 17]. Other significant but rare adverse effects of statins include new-onset diabetes [18] or muscle damage such as myopathy or rhabdomyolysis [15].

Overall, lifetime statin regimens have proven to be cost-effective [19] and are currently recommended for patients with a history of cardiovascular diseases, or in primary prevention based on factors such as pre-treatment cardiovascular risk, LDL-C levels, or comorbidity [20–23]. Since 2014, the National Institute for Health and Care Excellence (NICE) guidelines for primary prevention recommended statin prescription in patients aged 40 and older with a 10-year cardiovascular risk above 10% (QRISK2 > 10%) [24]. This threshold was set to prevent cardiovascular events in patients considered at moderate risk. These guidelines also suggested considering statins if other factors such as family history, socioeconomic factors, or patient preference might indicate an underestimated cardiovascular risk. The 2023 update reinforces the importance of shared decision-making, allowing statin use even for patients with a risk lower than 10% if the patient has an informed preference or if the risk might be underestimated. This update also recommends using the QRISK3 tool for cardiovascular risk assessment, which accounts for additional risk factors such as chronic kidney disease, severe mental illness, and migraine, and emphasises flexibility and patient autonomy in making treatment decisions [25, 26].

Despite the favourable benefit–risk profile of statins, concerns exist regarding treatment adherence in primary or secondary cardiovascular disease prevention [27]. Consequently, optimal lowering of LDL-C is not achieved within two years in over half of the patients initiated on statin therapy, significantly elevating their risk of future cardiovascular disease [28]. On the other hand, the effectiveness of statins for primary stroke prevention [29], even in patients without substantial cardiovascular risk factors [13], suggests a potential for broader use of statins in primary prevention of stroke in patients with hypercholesterolaemia.

In line with these observations, our objective in this study is to better understand the association between the onset of stroke and statin prescription in patients with hypercholesterolaemia, using routinely collected electronic health records in a multiethnic, youthful, and urban population. Accordingly, we have estimated the impact of statin prescription on stroke hazard in patients with hypercholesterolaemia. The association between statin prescription and patients' sociodemographic characteristics was also evaluated.

Method

Study participants

The study was conducted in the Lambeth borough in South London, characterised by a multiethnic, youthful, and deprived population. We utilised primary care electronic health records from adult patients aged over 18 and registered in one of the 41 Lambeth general practices between April 2005 and April 2021. The proportion of patients dropping out from the anonymised data-sharing scheme was 3.2%. These patients were not included in the study.

Primary care data

Electronic health records included the date of diagnoses of 18 long-term conditions coded in accordance with the Quality and Outcomes Framework (QOF), based on QOF38 definitions [30]. Long-term conditions included stroke, hypertension, diabetes, hypercholesterolaemia (total cholesterol > 5.0 mmol/L), atrial fibrillation, heart failure, myocardial infarction, chronic kidney disease stage 3 to 5, and transient ischaemic attack. Other information included gender (self-ascribed), ethnicity (Asian ethnicity, Black ethnicity, mixed ethnicity, other/unknown ethnicity, and White ethnicity), 'ever smoking' status, and the Index of Multiple Deprivation (IMD) 2019 (from 1-most deprived to 5-least deprived, based on seven domains of deprivation including income, employment, education, health, crime, housing, and quality of living environment). From available records, long-term conditions eligible for primary prevention include diabetes and chronic kidney disease stage 3 to 5. Likewise, patients eligible for secondary prevention are patients with a history of cardiovascular disease, defined as coronary heart disease, heart failure, stroke, peripheral arterial or vascular disease, myocardial infarction, atrial fibrillation, or transient ischaemic attack. History of heart disease was defined by at least one record of myocardial infarction, heart failure, coronary heart disease or atrial fibrillation. Likewise, history of cardiovascular diseased was defined by history of heart disease or at least one record of transient ischemic attack, peripheral arterial/vascular disease.

Statistical analyses

Covariates were censored at time of stroke in patients with a record of stroke or time to last follow-up for other patients. Long-term conditions, sociodemographic covariates, and other

variables were displayed as frequencies or median and interquartile range as appropriate.
The cause-specific hazard of stroke in patients with hypercholesterolaemia, in relation to statin prescription, sociodemographic covariates, and stroke risk factors, was evaluated using a multivariable Cox proportional hazards model allowing for time-varying exposure for statin prescription, i.e., time at record of first statin prescription. The proportional hazards assumption regarding variables fixed at baseline was assessed using the Schoenfeld residual-based test. Patients' follow-up was administratively censored to ensure that the proportional hazards assumption was satisfied.
The association between statin prescription, sociodemographic covariates, and stroke risk factors in patients with hypercholesterolaemia was evaluated using multivariable logistic regression. This model was also adjusted for age, with follow-up censored at the age of stroke for patients who experienced a stroke and at the age at last follow-up for other patients. Model calibration was visually assessed by plotting predicted probabilities of statin prescription against observed proportions per decile of predicted probabilities. The area under the receiver operating characteristic curve (AUC) was also computed to evaluate the model's discriminative ability.
Patients with missing covariates were excluded from models where these covariates were used as confounders.
All computations were carried out using the R language and environment for statistical computing (version 4.3.0 (2023-04-21)) [31].

Ethics

This study was conducted in accordance with the Declaration of Helsinki. Data were provided by the Lambeth DataNet upon approval for the analysis of fully anonymised data by the Lambeth Clinical Commissioning Group. All patients were informed through 'Fair Processing Notices' of the potential use of collected electronic health records in 'secondary data analysis' and were given the option to opt out of the data-sharing scheme [32]. Accordingly, this study was exempt from ethics committee approval and individual consent requirements as per the National Institute for Health (NIH) Health Research Authority (HRA) guidelines for research using anonymised primary care data in the United Kingdom.

Patient and public involvement

This research project actively involved patients and the public at several stages, including study design and dissemination strategies. Feedback was gathered from two Patient and Public Involvement groups, organised by the NIHR Biomedical Research Centres, including stroke and cardiovascular patient groups. These consultations were invaluable in shaping our approach to data use, confidentiality, and research ethics.
To ensure transparency and better inform the public about Lambeth DataNet research outcomes, the results of this research will be disseminated widely. Efforts will involve sharing findings with the public through accessible platforms, including community websites and publications,

as recommended by the Lambeth DataNet engagement groups. The results will also be communicated to local community groups, healthcare professionals, and Patient and Public Involvement groups to continue the discussion and identify further areas of research.

Results

Patient characteristics

Patient characteristics are summarised in Table 1. Briefly, of 166,124 patients with hypercholesterolaemia, 8.3%, 21.9%, 3.7%, and 54.4% self-identified as being of either Asian, Black, Mixed, or White ethnicity, and 11.6% were of other or unknown ethnicity. Female gender (self-ascribed) represented 50.6%. Gender was not declared by three patients. The IMD was available for 164,322 (98.9%) patients. Patients of White and Asian ethnicity had similar IMD profiles, whereas patients of Black ethnicity were overrepresented in IMD quintiles 1 and 2 (most deprived) and conversely less represented in quintiles 4 and 5 (least deprived).

Risk factors, statin prescription, and stroke

Patients with hypercholesterolaemia and stroke represented respectively 19.54% (n=166124) and 1.15% (n=9847) of all registered patients (n=849,968). Among them, 33.5% were prescribed statins versus 1.3% in other patients, and 4,390 patients (2.6%) had a record of stroke. These patients represented also 44.6% of all patients with stroke in the registry. Hypertension (67.5%) and diabetes (29.7%) were the two major metabolic stroke risk factors recorded for these patients, along with a history of heart disease (25.1%) and atrial fibrillation (12.6%). Patients of Black ethnicity were overrepresented among patients with a record of stroke (26.6% vs. 21.8%), and conversely, patients of White ethnicity were slightly underrepresented (52.4% vs. 54.5%). Statins were prescribed in 33.5% of patients with hypercholesterolaemia and 32.9% of patients with stroke. The proportion of patients with a record of diabetes diagnosed after the age of 40 or lasting more than 10 years, or chronic kidney disease stages 3 to 5, was 19.4%, of whom 79.5% were prescribed statin therapy in accordance with current guidelines on primary prevention (Table 1). Likewise, the proportion of patients with a history of cardiovascular disease, and therefore eligible for statin therapy in secondary prevention, was 10.5%. Among these patients, 81.4% were prescribed statins (Table 1).

Association between statin prescription and stroke

The cause-specific hazard of stroke was assessed using a Cox proportional hazards model . To account for variation in the baseline hazard and to ensure that the proportional hazards assumption holds, the model was stratified by history of heart disease, and the follow-up was administratively censored at 79 years. The modified dataset included 161527 patients with a record of hypercholesterolaemia (97.2%). The Schoenfeld test indicated no violation of the proportional hazards' assumption at the 5% level for all variables fixed at baseline. Coefficients of the multivariable cause-specific hazard model are depicted in Figure 1. This model shows that statin prescription, female gender, and levels of deprivation from 3 to 5 (least deprived) were significantly associated with lower hazard of stroke. Black, Asian, and Mixed ethnicity (compared to White ethnicity), ever smoking status, hypertension and diabetes were significantly associated with higher hazard of stroke.



Figure 1: *Multivariable cause-specific hazard ratio of statin prescription on stroke (allowing for time-varying exposure to statin prescription), adjusted for sociodemographics and stroke risk factors, and stratified by indicator of history of heart diseases, in patients with recorded hypercholesterolaemia, administratively censored at 79 years (n=159,757; number of events: 3,081; and 1,770 observations deleted due to missing covariates).*

Statin prescription in patients with hypercholesterolaemia

Figure 2 displays the multivariable odds ratios of statin prescription status associated with patients' sociodemographic characteristics and stroke risk factors in patients with hypercholesterolaemia. As expected, statin prescription was strongly associated with stroke risk factors, particularly diabetes and hypertension, and, to a lesser extent, ever-smoking status. As compared to White patients, Black patients were less likely to be prescribed statin therapy,

whereas Asian patients were more likely to be prescribed statins. Finally, female patients were also less likely to be prescribed statins than male patients. Supplementary figure 1 presents the calibration plot for the logistic regression displayed in figure 2. Calibration plots are used to visually assess the agreement between predicted probabilities from a model and observed proportions. In our setting it displays predicted probabilities of statin prescription derived from the fitted logistic model vs. observed proportions of patients prescribed statin therapy, by decile of the predicted probabilities. A well-calibrated model should display points lying close to the 45-degree line, showing that the logistic regression model fits the data adequately, yielding reliable predicted probabilities. Supplementary figure 1 indicates overall good calibration, with predicted probabilities generally close to observed proportions across deciles. This visual result aligns with an area under the receiver operating characteristic curve of 87%, also indicating an overall good model discrimination.

Variable		N	Odds ratio	p
Censored time to stroke		159757	1.06 (1.06, 1.06)	<0.001
Gender	Male	79678	Reference	
	Female	80079	0.72 (0.70, 0.74)	<0.001
Ethnicity	White	86455	Reference	
	Black	35369	0.79 (0.76, 0.82)	<0.001
	Asian	13495	1.65 (1.57, 1.74)	<0.001
	Mixed	5996	0.98 (0.91, 1.06)	0.67
	Other	4580	1.16 (1.07, 1.26)	<0.001
	Unknown	13862	0.76 (0.73, 0.80)	<0.001
IMD local quintile	1 (most deprived)	34774	Reference	
	2	33459	1.01 (0.97, 1.05)	0.73
	3	28437	0.94 (0.90, 0.99)	0.01
	4	29661	0.97 (0.93, 1.01)	0.14
	5 (least deprived)	33426	0.91 (0.87, 0.95)	<0.001
Smoking ever	No	74176	Reference	
	Yes	85581	1.33 (1.30, 1.37)	<0.001
Hypertension	No	111376	Reference	
	Yes	48381	2.97 (2.89, 3.06)	<0.001
Diabetes	No	134710	Reference	
	Yes	25047	11.13 (10.70, 11.58)	<0.001
History of heart diseases	No	148340	Reference	
	Yes	11417	4.72 (4.45, 5.00)	<0.001



Figure 2: *Multivariable odds ratio of statin prescription associated with sociodemographics and stroke risk factors in patients with hypercholesterolaemia (n= 164319 and 1805 observations deleted due to missing covariates)*

Discussion

In this study, we set out to better understand the association between the onset of stroke and statin prescription in patients with hypercholesterolaemia, using routinely collected electronic health records in a multiethnic, youthful, and urban population. Our results highlights the complexity of the relationship between hypercholesterolaemia and stroke, but also the preventive effect of statins against stroke in patients with hypercholesterolaemia. Analysing the impact of statin prescription on stroke risk in observational studies is challenging. This is due mainly to indication bias where the likelihood of receiving statins, for instance, is itself associated with the underlying stroke risk factors [33]. The use of time-to-event models, accounting for delayed records of statin prescription mitigates confounding by indication, while avoiding immortal time bias, which occurs when unexposed time is incorrectly attributed based on future statin prescriptions. This was illustrated by a clear and significant downward effect of statin prescription on the hazard of stoke in the Cox model adjusted for sociodemographic covariates and stroke risk factors in patients with hypercholesterolaemia (cause-specific hazard: 0.74, 95% confidence interval: 0.68-0.80, $p < 0.001$, Figure 1).

These observations raise questions, including the optimal prescription of statins in patients with hypercholesterolaemia and the role of statins' pleiotropic effects [34] in delaying or preventing stroke onset in this population. In our study, 44.6% of patients with stroke had a history of hypercholesterolaemia, and among them, 61.1% were prescribed statins. This suggests that these patients were appropriately identified as being at higher risk for cardiovascular disease and accordingly were prescribed statin therapy, nearly twice the rate observed in other patients with hypercholesterolaemia (32.7%). While stroke could not be avoided in these patients, our data suggest that stroke may have been delayed in patients prescribed statins. Additionally, the post hoc analysis among patients with a history of stroke suggests that a substantial proportion could have benefited from statin therapy, potentially reducing their stroke risk. This perspective supposes, however, that statin therapy is further prescribed to patients with untreated hypercholesterolaemia, which represents 13.0% (n=110,522) of the registry population, but does not align with the current prevention policy. Another perspective reveals that only 1.5% of patients with untreated hypercholesterolaemia experienced a stroke, which is significantly lower than in patients with prescribed statins (Table 1), but is also slightly higher than the prevalence of stroke in the registry (1.2%). The multivariable analysis of patients' sociodemographic characteristics and stroke risk factors on statin prescription also shows that statins were prescribed according to current guidelines [22], that is, in patients with a history of cardiovascular disease and associated risk factors, including hypertension and diabetes. However, this analysis also reveals that female patients and patients of Black ethnicity were less likely to be prescribed statin therapy compared to male patients and patients of White and Asian ethnicity, respectively. This tendency may be due to implicit ethnicity-based biases by healthcare providers [35], misconceptions that women are at lower risk of cardiovascular disease [36, 37], or patient perceptions and beliefs regarding cardiovascular risk and statin therapy [38]. This tendency may also be linked with our

previous observation that patients of Black ethnicity with hypercholesterolaemia had a higher risk of stroke compared to their counterparts of White and Asian ethnicity [39].

Of note, our analysis is based on recorded statin prescriptions. In other words, depending on treatment adherence and treatment gaps [27], prescriptions overestimate the actual exposure to statin therapy. As a consequence, it is likely that the true effect of statin therapy on stroke hazard is underestimated in our study. Conversely, depending on gender and ethnic patterns in statin therapy adherence, which appears to be lower in ethnic subgroups and women [40], it is also likely that the effect of gender and ethnicity on the risk of stroke is distorted. For instance, the higher risk of stroke observed in patients of non-White ethnicity is likely to be confounded with lower adherence in these patients, whereas the gender effect is likely to be underestimated as female patients exhibit both a lower risk of stroke and lower adherence to statin therapy. More generally, in addition to potential bias, including adherence bias, as discussed above, limitations and strengths of our study relate to both the use of routinely collected primary care electronic health records and the population under study. Although primary care electronic health records are widely regarded as a dependable data source and are increasingly utilised for research, surveillance, and public health planning [41, 42], the accuracy and completeness of recorded information may raise concerns. For example, records such as patients' current smoking status, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and QRISK3 score were not available in the electronic health records considered in this study. Finally, the characteristics of the analysed population are important aspects to consider, as they may either support or limit specific study objectives. If the relative geographical and environmental uniformity within Lambeth borough, along with its diverse population, facilitates the identification of biases, such as inequalities in statin prescription practices, these characteristics should, however, be taken into account when attempting to generalise the study results to other settings.

Conclusion

This study focused on statin prescription and the risk of stroke in patients with diagnosed hypercholesterolaemia. Overall, our results show a protective effect of statins on stroke hazard in a real life setting. Further insights reveal that guidelines for statin prescription are generally well followed by general practitioners, although post hoc analysis suggests that a small proportion of patients with untreated hypercholesterolaemia may have benefited from statin therapy. In line with NICE (updated) guidelines on statin prescription, our results further suggest that in uncertain or complex situations, and according to patients' informed preference, comorbidity, sociodemographic characteristics, and ethnic background, statin therapy prescription may be extended with potential benefit, even if patients do not present a 10-year cardiovascular risk higher than 10%. Finally, we recommend that further efforts be made to address disparities observed in statin prescription across gender groups and ethnic groups.

List of abbreviations

HHD: History of Heart Disease

FH: Familial Hypercholesterolaemia

LDL-C: Low-Density Lipoprotein Cholesterol

NICE: National Institute for Health and Care Excellence

QRISK2: Cardiovascular Risk Assessment Tool version 2

QRISK3: Cardiovascular Risk Assessment Tool version 3

QOF: Quality and Outcomes Framework

IMD: Index of Multiple Deprivation

NIH: National Institutes of Health

HRA: Health Research Authority

CI: Confidence Interval

HDL: High-Density Lipoprotein

LDL: Low-Density Lipoprotein

NIHR: National Institute for Health and Care Research

AUC: Area Under the receiver operating characteristic Curve

Declarations

Ethics approval and consent to participate

Data were provided by the Lambeth DataNet upon approval for the analysis of fully anonymised data by the Lambeth Clinical Commissioning Group. All patients were informed through 'Fair Processing Notices' of the potential use of collected electronic health records in 'secondary data analysis' and were given the option to opt out of the data-sharing scheme. Accordingly, this study was exempt from ethics committee approval and individual consent requirements as per the National Institute for Health (NIH) Health Research Authority (HRA) guidelines for research using anonymised primary care data in the United Kingdom.

Consent for publication

Not applicable

Availability of data and materials

Data supporting this study can be obtained from the Lambeth Datanet subject to IRB approval, and are not publicly available.

Competing interests

The authors declare no competing interests.

Funding

This project is funded by King's Health Partners / Guy's and St Thomas Charity (grant number EIC180702) and support from the National Institute for Health and Care Research (NIHR) under its Programme Grants for Applied Research (NIHR202339).

Authors' contributions

MD designed the study (conceptualisation and methodology); AD acquired the data; MD carried out data curation; MD and AD conducted investigations; MD developed computer code and performed formal analysis, including data visualisation and validation; MD and AD interpreted the data. MD drafted the manuscript, and AD supervised the research. MD and AD reviewed, edited, and approved the final version of the manuscript.

Acknowledgments

We would like to thank Dr Salma Ayis for her continuous help and support throughout the course of this work.

References

[1] Joshua Willey and Marco Gonzalez-Castellon. Cholesterol level and stroke: a complex relationship. *JAMA internal medicine*, 173(19):1765–1766, 2013.

[2] Yurong Zhang, Jaakko Tuomilehto, Pekka Jousilahti, Yujie Wang, Riitta Antikainen, and Gang Hu. Total and high-density lipoprotein cholesterol and stroke risk. *Stroke*, 43:1768–1774, 7 2012.

[3] LB Goldstein, P Amarenco, M Szarek, A Callahan III, M Hennerici, H Sillesen, JA Zivin, and KMA Welch. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. *Neurology*, 70(24_part_2):2364–2370, 2008.

[4] Xiang Wang, Yan Dong, Xiangqian Qi, Chengguang Huang, and Lijun Hou. Cholesterol levels and risk of hemorrhagic stroke: A systematic review and meta-analysis. *Stroke*, 44:1833–1839, 7 2013.

[5] S. MacMahon, S. Duffy, A. Rodgers, S. Tominaga, L. Chambless, G. De Backer, D. De Bacquer, M. Kornitzer, P. Whincup, S. G. Wannamethee, R. Morris, N. Wald, J. Morris, M. Law, M. Knuiman, H. Bartholomew, G. Davey Smith, P. Sweetnam, P. Elwood, J. Yarnell, R. Kronmal, D. Kromhout, S. Sutherland, J. Keil, G. Jensen, P. Schnohr, C. Hames, A. Tyroler, A. Aromaa, P. Knekt, A. Reunanen, J. Tuomilehto, P. Jousilahti, E. Vartiainen, P. Puska, T. Kuznetsova, T. Richart, J. Staessen, L. Thijs, T. Jorgensen, T. Thomsen, D. Sharp, J. D. Curb, N. Qizilbash, H. Iso, S. Sato, A. Kitamura, Y. Naito, A. Benetos, L. Guize, U. Goldbourt, M. Tomita, Y. Nishimoto, T. Murayama, M. Criqui, C. Davis, C. Hart, D. Hole, C. Gillis, D. Jacobs, H. Blackburn, R. Luepker, J. Neaton, L. Eberly, C. Cox, D. Levy, R. D'Agostino, H. Silbershatz, A. Tverdal, R. Selmer, T. Meade, K. Garrow, J. Cooper, F. Speizer, M. Stampfer, A. Menotti, A. Spagnolo, I. Tsuji, Y. Imai, T. Ohkubo, S. Hisamichi, L. Haheim, I. Holme, I. Hjermann, P. Leren, P. Ducimetiere, J. Empana, K. Jamrozik, R. Broadhurst, G. Assmann, H. Schulte, C. Bengtsson, C. Björkelund, L. Lissner, P. Sorlie, M. Garcia-Palmieri, E. Barrett-Connor, R. Langer, K. Nakachi, K. Imai, X. Fang, S. Li, R. Buzina, A. Nissinen, C. Aravanis, A. Dontas, A. Kafatos, H. Adachi, H. Toshima, T. Imaizumi, S. Nedeljkovic, M. Ostojic, Z. Chen, H. Tunstall-Pedoe, T. Nakayama, N. Yoshiike, T. Yokoyama, C. Date, H. Tanaka, J. Keller, K. Bonaa, E. Arnesen, E. Rimm, M. Gaziano, J. E. Buring, C. Hennekens, S. Törnberg, J. Carstensen, M. Shipley, D. Leon, M. Marmot, J. Armitage, C. Baigent, R. Clarke, R. Collins, J. Emberson, J. Halsey, M. Landray, S. Lewington, A. Palmer, S. Parish, R. Peto, P. Sherliker, and G. Whitlock. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet (London, England)*, 370:1829–1839, 12 2007.

[6] Melissa A Austin, Carolyn M Hutter, Ron L Zimmern, and Steve E Humphries. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review. *American journal of epidemiology*, 160(5):407–420, 2004.

[7] F. Barkas, M. Elisaf, and H. Milionis. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. *Atherosclerosis*, 243(1):60–64, 2015.

[8] A. Hovland, L. Mundal, J. Igland, M. B. Veierød, K. B. Holven, M. P. Bogsrud, G. S. Tell, T. P. Leren, and K. Retterstøl. Risk of ischemic stroke and total cerebrovascular disease in familial hypercholesterolemia: A register study from norway. *Stroke*, 50(1):172–174, 2018.

[9] S. O. Beheshti, C. M. Madsen, A. Varbo, M. Benn, and B. G. Nordestgaard. Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: Copenhagen general population study. *Circulation*, 138(6):578–589, 2018.

[10] Hiroyasu Iso, David R. Jacobs, Deborah Wentworth, James D. Neaton, and Jerome D. Cohen. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. *New England Journal of Medicine*, 320:904–910, 4 1989.

[11] Epidemiological Studies Unit. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*, 366(9493):1267–1278, 2005.

[12] C. Baigent, L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, R. Collins, J. De Lemos, E. Braunwald, M. Blazing, S. Murphy, J. R. Downs, A. Gotto, M. Clearfield, H. Holdaas, D. Gordon, B. Davis, M. Koren, B. Dahlof, N. Poulter, P. Sever, R. H. Knopp, B. Fellström, A. Jardine, R. Schmieder, F. Zannad, U. Goldbourt, E. Kaplinsky, H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, J. Fuller, A. Neil, C. Wanner, V. Krane, F. Sacks, L. Moyé, M. Pfeffer, C. M. Hawkins, P. Barter, L. Tavazzi, A. Maggioni, R. Marchioli, G. Tognoni, M. G. Franzosi, H. Bloomfield, S. Robins, J. Armitage, S. Parish, P. Sleight, T. R. Pedersen, P. M. Ridker, R. Holman, T. Meade, S. MacMahon, I. Marschner, A. Tonkin, J. Shaw, P. W. Serruys, H. Nakamura, G. Knatterud, C. Furberg, R. Byington, P. Macfarlane, S. Cobbe, I. Ford, M. Murphy, G. J. Blauw, C. Packard, J. Shepherd, J. Kjekshus, L. Wilhelmsen, C. Cannon, L. Bowman, A. Baxter, M. Landray, J. La Rosa, J. Rossouw, J. Probstfield, M. Flather, J. Kastelein, C. Newman, C. Shear, J. Tobert, J. Varigos, H. White, S. Yusuf, M. Mellies, M. McGovern, J. Barclay, R. Belder, Y. Mitchel, T. Musliner, J. C. Ansquer, M. Llewellyn, M. Bortolini, G. Brandrup-Wognsen, B. Bryzinski, G. Olsson, J. Pears, D. De Micco, G. Buck, W. G. Herrington, P. M. Kearney, A. Kirby, D. A. Lewis, C. Pollicino, and T. Sourjina. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. *The Lancet*, 376:1670–1681, 11 2010.

[13] B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, C. Baigent, J. De Lemos, E. Braunwald, M. Blazing, S. Murphy, J. R. Downs, A. Gotto, M. Clearfield, H. Holdaas, D. Gordon, B. Davis, M. Koren, B. Dahlof, N. Poulter, P. Sever, R. H. Knopp, B. Fellstrom, A. Jardine, R. Schmieder, F. Zannad, U. Goldbourt, E. Kaplinsky, H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, J. Fuller, A. Neil, C. Wanner, V. Krane, F. Sacks, L. Moye, M. Pfeffer, C. M. Hawkins, J. Kjekshus, H. Wedel, J. Wikstrand, P. Barter, L. Tavazzi, A. Maggioni, R. Marchioli, G. Tognoni, M. G. Franzosi, H. Bloomfield, S. Robins, J. Armitage, S. Parish, R. Peto, P. Sleight, T. R. Pedersen, P. M. Ridker, R. Holman, T. Meade, S. MacMahon, I. Marschner, A. Tonkin, J. Shaw, P. W. Serruys, H. Nakamura, G. Knatterud, C. Furberg, R. Byington, P. MacFarlane, S. Cobbe, I. Ford, M. Murphy, G. J. Blauw, C. Packard, J. Shepherd, L. Wilhelmsen, C. Cannon, L. Bowman, M. Landray, J. La Rosa, J. Rossouw, J. Probstfi Eld, M. Flather, J. Kastelein, C. Newman, C. Shear, J. Tobert, J. Varigos, H. White, S. Yusuf, M. Mellies, M. McGovern, J. Barclay, R. Belder, Merck Y. Mitchel, T. Musliner, J. C. Ansquer, Bayer M. Llewellyn, Novartis Pharma, M. Bortolini, G. Brandrup-Wognsen, B. Bryzinski, G. Olsson, J. Pears, D. DeMicco, A. Baxter, N. Bhala, G. Buck, W. G. Herrington, L. E. Holland, P. M. Kearney, A. Kirby, D. A. Lewis, C. Pollicino, C. Reith, and T. Sourjina. The effects of lowering ldl cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *The Lancet*, 380:581–590, 8 2012.

[14] Karianne Svendsen, Thomas Olsen, Kathrine J. Vinknes, Liv J. Mundal, Kirsten B. Holven, Martin P. Bogsrud, Trond P. Leren, Jannicke Igland, and Kjetil Retterstøl. Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study. *Atherosclerosis*, 358:34–40, 10 2022.

[15] Malcolm Law and Alicja R. Rudnicka. Statin safety: A systematic review. *The American Journal of Cardiology*, 97:S52–S60, 4 2006.

[16] Christina Reith, Colin Baigent, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Lisa Holland, Kate Wilson, Jane Armitage, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *The Lancet*, 400(10355):832–845, 2022.

[17] Emily Herrett, Elizabeth Williamson, Kieran Brack, Danielle Beaumont, Alexander Perkins, Andrew Thayne, Haleema Shakur-Still, Ian Roberts, Danielle Prowse, Ben Goldacre, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *bmj*, 372, 2021.

[18] Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*, 375(9716):735–742, 2010.

[19] Borislava Mihaylova, Runguo Wu, Junwen Zhou, Claire Williams, Iryna Schlackow, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Richard Parnell, Jane Armitage, Alastair Gray, John Simes, and Colin Baigent. Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the uk: a microsimulation modelling study. *The Lancet Regional Health - Europe*, 40:100887, 5 2024.

[20] Frank LJ Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José-Manuel Boavida, Davide Capodanno, et al. 2021 esc guidelines on cardiovascular disease prevention in clinical practice: Developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the european society of cardiology and 12 medical societies with the special contribution of the european association of preventive cardiology (eapc). *European heart journal*, 42(34):3227–3337, 2021.

[21] Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah De Ferranti, Joseph Faiella-Tommasino, Daniel E Forman, et al. 2018 aha/acc/aacvpr/aapa/abc/acpm/ada/ags/apha/aspc/nla/pcna guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. *Journal of the American College of Cardiology*, 73(24):e285–e350, 2019.

[22] NICE guideline CG181. Cardiovascular disease: risk assessment and reduction, including lipid modification. *Methods*, 2023.

[23] Sam Finnikin, Brian Finney, Rani Khatib, and James McCormack. Statins, risk, and personalised care. *bmj*, 384, 2024.

[24] National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. `https://www.nice.org.uk/guidance/cg181`, 2014. CG181.

[25] Julia Hippisley-Cox, Carol Coupland, and Peter Brindle. Development and validation of qrisk3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*, 357:j2099, 2017.

[26] National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023. Accessed: 2024-02-11.

[27] Alexander Pate, Rachel A Elliott, Georgios Gkountouras, Alexander Thompson, Richard Emsley, and Tjeerd van Staa. The impact of statin discontinuation and restarting rates on the optimal time to initiate statins and on the number of cardiovascular events prevented. *Pharmacoepidemiology and Drug Safety*, 29(6):644–652, 2020.

[28] Ralph Kwame Akyea, Joe Kai, Nadeem Qureshi, Barbara Iyen, and Stephen F. Weng. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. *Heart*, 105:975–981, 7 2019.

[29] Pierre Amarenco and Julien Labreuche. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *The Lancet Neurology*, 8(5):453–463, 2009.

[30] NHS Digital. Quality and Outcomes Framework (QOF) Business Rules v38: 2017-2018 October Code Release, October 2018. Available from: `https://webarchive.nationalarchives.gov.uk/ukgwa/20221104222820/https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof#quality-and-outcome-framework-business-rules`.

[31] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2023.

[32] NHS England. Privacy Notice - NHS England and NHS Improvement. https://www.england.nhs.uk/contact-us/privacy-notice/find-out-what-a-privacy-notice-is/. Accessed on 2024-04-01.

[33] KS Joseph, Azar Mehrabadi, and Sarka Lisonkova. Confounding by indication and related concepts. *Current Epidemiology Reports*, 1(1):1–8, 2014.

[34] James K Liao and Ulrich Laufs. Pleiotropic effects of statins. *Annu. Rev. Pharmacol. Toxicol.*, 45(1):89–118, 2005.

[35] Irene V Blair, Edward P Havranek, David W Price, Rebecca Hanratty, Diane L Fairclough, Tillman Farley, Holen K Hirsh, and John F Steiner. Assessment of biases against latinos and african americans among primary care providers and community members. *American journal of public health*, 103(1):92–98, 2013.

[36] Lori Mosca, Elizabeth Barrett-Connor, and Nanette Kass Wenger. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. *Circulation*, 124(19):2145–2154, 2011.

[37] Min Zhao, Mark Woodward, Ilonca Vaartjes, Elizabeth RC Millett, Kerstin Klipstein-Grobusch, Karice Hyun, Cheryl Carcel, and Sanne AE Peters. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. *Journal of the American Heart Association*, 9(11):e014742, 2020.

[38] Michael G Nanna, Ann Marie Navar, Pearl Zakroysky, Qun Xiang, Anne C Goldberg, Jennifer Robinson, Veronique L Roger, Salim S Virani, Peter WF Wilson, Joseph Elassal, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry. *JAMA cardiology*, 3(8):739–748, 2018.

[39] Marc Delord, Mark Ashworth, and Abdel Douiri. Does ethnicity alters the risk of stroke in patients with modifiable cardiometabolic risk factors? *medRxiv*, 2024.

[40] Jennifer Lewey, William H. Shrank, Ashna D.K. Bowry, Elaine Kilabuk, Troyen A. Brennan, and Niteesh K. Choudhry. Gender and racial disparities in adherence to statin therapy: A meta-analysis. *American Heart Journal*, 165:665–678.e1, 5 2013.

[41] Nicole Gray Weiskopf and Chunhua Weng. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. *Journal of the American Medical Informatics Association*, 20(1):144–151, 2013.

[42] Clemens Scott Kruse, Anna Stein, Heather Thomas, and Harmander Kaur. The use of electronic health records to support population health: a systematic review of the literature. *Journal of medical systems*, 42(11):214, 2018.